KR20010012374A - 지속 효과를 갖는 서방성 겔 - Google Patents

지속 효과를 갖는 서방성 겔 Download PDF

Info

Publication number
KR20010012374A
KR20010012374A KR1019997010326A KR19997010326A KR20010012374A KR 20010012374 A KR20010012374 A KR 20010012374A KR 1019997010326 A KR1019997010326 A KR 1019997010326A KR 19997010326 A KR19997010326 A KR 19997010326A KR 20010012374 A KR20010012374 A KR 20010012374A
Authority
KR
South Korea
Prior art keywords
composition
biologically active
protein
alginate
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019997010326A
Other languages
English (en)
Korean (ko)
Inventor
골든버그메릴시머
빅맨앨리스씨
구지안화
Original Assignee
스티븐 엠. 오드레
암젠 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스티븐 엠. 오드레, 암젠 인코포레이티드 filed Critical 스티븐 엠. 오드레
Publication of KR20010012374A publication Critical patent/KR20010012374A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1019997010326A 1997-05-16 1998-05-18 지속 효과를 갖는 서방성 겔 Ceased KR20010012374A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85797397A 1997-05-16 1997-05-16
US?08/857,973? 1997-05-16
US91290297A 1997-08-15 1997-08-15
US?08/912,902? 1997-08-15

Publications (1)

Publication Number Publication Date
KR20010012374A true KR20010012374A (ko) 2001-02-15

Family

ID=27127437

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997010326A Ceased KR20010012374A (ko) 1997-05-16 1998-05-18 지속 효과를 갖는 서방성 겔

Country Status (18)

Country Link
EP (1) EP0981374B1 (enExample)
JP (1) JP2001525826A (enExample)
KR (1) KR20010012374A (enExample)
AU (1) AU7491898A (enExample)
BG (1) BG64860B1 (enExample)
BR (1) BR9809117A (enExample)
CA (1) CA2289196C (enExample)
CZ (1) CZ299180B6 (enExample)
DE (1) DE69838750T2 (enExample)
EA (1) EA199901013A1 (enExample)
ES (1) ES2294814T3 (enExample)
HU (1) HUP0003393A3 (enExample)
IL (1) IL132814A0 (enExample)
NO (1) NO995591D0 (enExample)
PL (1) PL199565B1 (enExample)
SK (1) SK286437B6 (enExample)
WO (1) WO1998051348A2 (enExample)
YU (1) YU58599A (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003200609B2 (en) * 1998-05-18 2006-02-23 Amgen Inc. Biodegradable sustained-release alginate gels
US6432449B1 (en) * 1998-05-18 2002-08-13 Amgen Inc. Biodegradable sustained-release alginate gels
JP2000256216A (ja) * 1999-03-04 2000-09-19 Meiji Milk Prod Co Ltd ゲル組成物
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
EP1233751A1 (en) * 1999-11-29 2002-08-28 ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, Inc. Sustained percutaneous delivery of a biologically active substance
FR2823119B1 (fr) * 2001-04-05 2004-02-20 Seppic Sa Adjuvant d'immunite contenant un cation metallique complexe et vaccin le contenant
MXPA05004299A (es) * 2002-10-25 2005-08-03 Pfizer Prod Inc Formulacion de liberacion prolongada de agentes activos arilheterociclicos en forma de suspension.
CN101309688B (zh) * 2005-05-23 2016-06-22 自然选择国际公司 持续释放β-丙氨酸的组合物和方法
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
JP5107585B2 (ja) * 2007-01-29 2012-12-26 株式会社 メドレックス 低温充填ゼリー組成物とその製造方法
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
CN106214321B (zh) 2010-10-15 2018-08-28 科尼尔赛德生物医学公司 用于进入眼睛的装置
EA034963B1 (ru) 2012-11-08 2020-04-13 Клиасайд Байомедикал, Инк. Способ лечения расстройства заднего сегмента глаза
CN105246529B (zh) 2013-05-03 2019-06-14 科尼尔赛德生物医学公司 用于眼部注射的设备和方法
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
EP3157598A4 (en) 2014-06-20 2018-05-16 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
JP2019514581A (ja) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド 眼の薬物送達のためのシステムおよび方法
CN110177527B (zh) 2016-08-12 2022-02-01 科尼尔赛德生物医学公司 用于调节药剂递送用针的插入深度的装置和方法
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
WO2019234010A1 (en) * 2018-06-04 2019-12-12 Spermvital As Functionalized kit for preparing hydrogels
EP3878476B1 (en) * 2018-11-06 2025-10-01 National Cancer Center Alginic acid-based injectable hydrogel system
JP2022550457A (ja) * 2019-10-01 2022-12-01 ブリリアン・ファーマ・インコーポレイテッド 肥満の処置又は防止及び体重管理の方法
EP4130235A4 (en) * 2020-03-26 2024-07-10 Osaka University SUPPORT BATH FOR THREE-DIMENSIONAL (3D) TISSUE CULTURE
CN114533653B (zh) * 2020-11-26 2023-12-22 上海凯茂生物医药有限公司 一种人促红素杂合Fc融合蛋白相变型制剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5416979B2 (enExample) * 1972-01-08 1979-06-26
US4241099A (en) * 1979-02-26 1980-12-23 Tiemstra Peter J Pectin formulations, products and methods having delayed-action acidulants
US4690682A (en) * 1983-04-15 1987-09-01 Damon Biotech, Inc. Sustained release
US4789516A (en) * 1983-04-15 1988-12-06 Damon Biotech, Inc Production of sustained released system
US4744933A (en) * 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
CA1215922A (en) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
JPS645460A (en) * 1987-06-29 1989-01-10 Sanei Kagaku Kogyo Kk Production of delaying gelatinous material
JPH0794583B2 (ja) * 1989-12-15 1995-10-11 株式会社大塚製薬工場 高含水高分子ゲル
IT1245383B (it) * 1991-03-28 1994-09-20 Eniricerche Spa Composizione acquosa gelificabile avente tempo di gelificazione ritardato
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
KR960006730B1 (ko) * 1993-02-11 1996-05-23 재단법인한국화학연구소 에멀젼 네트웍(emulsion network)을 이용한 약물의 피부 전달체계
GB9708773D0 (en) * 1997-04-30 1997-06-25 Reckitt & Colmann Prod Ltd Organic compositions

Also Published As

Publication number Publication date
CA2289196C (en) 2007-08-07
JP2001525826A (ja) 2001-12-11
HUP0003393A2 (hu) 2001-02-28
ES2294814T3 (es) 2008-04-01
SK286437B6 (sk) 2008-10-07
EP0981374B1 (en) 2007-11-21
BG103914A (en) 2000-07-31
DE69838750D1 (de) 2008-01-03
IL132814A0 (en) 2001-03-19
DE69838750T2 (de) 2008-10-30
EP0981374A2 (en) 2000-03-01
AU7491898A (en) 1998-12-08
WO1998051348A3 (en) 1999-02-18
NO995591L (no) 1999-11-15
BG64860B1 (bg) 2006-07-31
NO995591D0 (no) 1999-11-15
CZ396399A3 (cs) 2000-04-12
PL336887A1 (en) 2000-07-17
SK154399A3 (en) 2000-07-11
WO1998051348A2 (en) 1998-11-19
BR9809117A (pt) 2000-08-01
PL199565B1 (pl) 2008-10-31
HUP0003393A3 (en) 2001-03-28
EA199901013A1 (ru) 2000-06-26
YU58599A (sh) 2000-12-28
CA2289196A1 (en) 1998-11-19
CZ299180B6 (cs) 2008-05-14

Similar Documents

Publication Publication Date Title
KR20010012374A (ko) 지속 효과를 갖는 서방성 겔
ES2283052T3 (es) Geles de alginato de liberacion sostenida.
US7374782B2 (en) Production of microspheres
CA2433037C (en) Sustained-release preparation
RS58599B1 (sr) Postupak za neinvazivno određivanje genetičkih varijacija
KR20010025023A (ko) 생분해가능한 서방성 알긴산 겔
US20010007673A1 (en) Sustained-release delayed gels
JP3283288B2 (ja) 生理活性ペプチド製剤
CN1263472A (zh) 缓释延迟凝胶剂
AU2005200949B2 (en) Sustained-Release Delayed Gels
CN1526372A (zh) 一种抑制突释效应的长效注射剂
MXPA99010284A (en) Sustained-release delayed gels
MXPA99009388A (en) Sustained-release alginate gels
MXPA00011231A (en) Biodegradable sustained-release alginate gels

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19991108

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20030519

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050228

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20050930

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20050228

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I